Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC).

Fifty-eight RCC patients, who had undergone surgery and had a maximum of 3 metastases, were treated with SBRT. Patients were followed for up to 5 years after SBRT.

Local control rate was 90.2% at both 12 and 18 months, and progression-free survival (PFS) rates were 46.2% and 35%, respectively. Median overall survival (OS) was 28.4 months, and 1-, 2-, and 5-year survival rates were 100%, 100%, and 83%, respectively.

The authors concluded that “future prospective studies are necessary to evaluate [SBRT’s] impact on survival and quality of life. Moreover, a new prospective on the radiobiology of RCC should be considered to better understand the role of SBRT and, particularly, its possible interaction with medical therapies.”

Read the full article in Cancer Therapy Advisor here

Share this Post!


Related post

  TOP